Free Trial

BTIG Research's Rating of Sensei Biotherapeutics on 6/11/2026

On June 11, 2026, BTIG Research updated its outlook on Sensei Biotherapeutics (NASDAQ:FTH) with the action "Upgrade", setting a "Strong-Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from BTIG Research

DateCompanyAction
6/17/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Reiterated Rating
6/17/2026
Lyft, Inc. stock logo
LYFT
Lyft
Upgrade
6/17/2026
Annaly Capital Management Inc stock logo
NLY
Annaly Capital Management
Set Price Target
6/17/2026
Dynex Capital, Inc. stock logo
DX
Dynex Capital
Set Price Target
6/16/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Reiterated Rating
6/16/2026
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
Reiterated Rating
More Ratings From BTIG Research